COBLL1, LPL and ZAP70 expression defines prognostic subgroups
of chronic lymphocytic leukemia patients with high accuracy and
correlates with IGHV mutational status

J 2017

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status

PLEŠINGEROVÁ, Hana, Zuzana LIBROVA, Karla PLEVOVÁ, Antonín LIBRA, Boris TICHÝ et. al.

Basic information

Original name

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status

Authors

PLEŠINGEROVÁ, Hana (203 Czech Republic, belonging to the institution), Zuzana LIBROVA (203 Czech Republic), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), Antonín LIBRA (203 Czech Republic), Boris TICHÝ (203 Czech Republic, belonging to the institution), Hana SKUHROVÁ FRANCOVÁ (203 Czech Republic, belonging to the institution), Filip VRBACKY (203 Czech Republic), Lukáš SMOLEJ (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution), Vítězslav BRYJA (203 Czech Republic, belonging to the institution), Michael DOUBEK (203 Czech Republic, belonging to the institution) and Šárka POSPÍŠILOVÁ (203 Czech Republic, guarantor, belonging to the institution)

Edition

LEUKEMIA & LYMPHOMA, Oxon, TAYLOR & FRANCIS LTD, 2017, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.644

RIV identification code

RIV/00216224:14740/17:00094368

Organization unit

Central European Institute of Technology

DOI

http://dx.doi.org/10.1080/10428194.2016.1180690

UT WoS

000387484400011

Keywords in English

Chronic lymphocytic leukemia; COBLL1; IGHV mutational status; LPL; prognosis; ZAP70

Abstract

V originále

The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Patients with unmutated IGHV (U-CLL) usually progress rapidly, whereas patients with mutated IGHV (M-CLL) have a more indolent disease. The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL. We analyzed the prognostic relevance of COBLL1, LPL, and ZAP70 gene expression, which correlated with IGHV mutational status (p< 0.0001), in 117 CLL patients and established a prognostic parameter dividing the tested cohort according to the disease aggressiveness. Our prognostic parameter was validated on an independent cohort of 161 CLL patients and achieved a high accuracy (94%). Patients divided according to the prognostic parameter differ in overall survival and time to first treatment (p< 0.0001, HR = 2.300/5.970, 95% CI: 1.587-3.450/4.621-15.86). Our approach provides a reliable alternative method to prognosis assessment via IGHV mutational status analysis.

Links

FR-TI2/254, research and development project

Name: *Real-time PCR soupravy pro diagnostiku v onkologii (Acronym: ONKOKITY)

Investor: Ministry of Industry and Trade of the CR

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

MUNI/A/1028/2015, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit III (Acronym: VýDiTeHeMa III)

Investor: Masaryk University, Category A

NV15-29793A, research and development project

Name: Analýza Wnt/PCP jako nástroj pro lepší management chronické lymfocytární leukémie

NV15-30015A, research and development project

Name: Analýza klonální heterogenity chronické lymfocytární leukemie pomoci sekvenování nové generace genu pro B-buněčný receptor. Národní studie.

TE02000058, research and development project

Name: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED)

Investor: Technology Agency of the Czech Republic

Citovat

PLEŠINGEROVÁ, Hana, Zuzana LIBROVA, Karla PLEVOVÁ, Antonín LIBRA, Boris TICHÝ, Hana SKUHROVÁ FRANCOVÁ, Filip VRBACKY, Lukáš SMOLEJ, Jiří MAYER, Vítězslav BRYJA, Michael DOUBEK and Šárka POSPÍŠILOVÁ. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. LEUKEMIA & LYMPHOMA. Oxon: TAYLOR & FRANCIS LTD, 2017, vol. 58, No 1, p. 70-79. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2016.1180690.

@article{1387521,
   author = {Plešingerová, Hana and Librova, Zuzana and Plevová, Karla and Libra, Antonín and Tichý, Boris and Skuhrová Francová, Hana and Vrbacky, Filip and Smolej, Lukáš and Mayer, Jiří and Bryja, Vítězslav and Doubek, Michael and Pospíšilová, Šárka},
   article_location = {Oxon},
   article_number = {1},
   doi = {http://dx.doi.org/10.1080/10428194.2016.1180690},
   keywords = {Chronic lymphocytic leukemia; COBLL1; IGHV mutational status; LPL; prognosis; ZAP70},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status},
   url = {http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1180690},
   volume = {58},
   year = {2017}
}

TY  - JOUR
ID  - 1387521
AU  - Plešingerová, Hana - Librova, Zuzana - Plevová, Karla - Libra, Antonín - Tichý, Boris - Skuhrová Francová, Hana - Vrbacky, Filip - Smolej, Lukáš - Mayer, Jiří - Bryja, Vítězslav - Doubek, Michael - Pospíšilová, Šárka
PY  - 2017
TI  - COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status
JF  - LEUKEMIA & LYMPHOMA
VL  - 58
IS  - 1
SP  - 70-79
EP  - 70-79
PB  - TAYLOR & FRANCIS LTD
SN  - 10428194
KW  - Chronic lymphocytic leukemia
KW  - COBLL1
KW  - IGHV mutational status
KW  - LPL
KW  - prognosis
KW  - ZAP70
UR  - http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1180690
L2  - http://www.tandfonline.com/doi/full/10.1080/10428194.2016.1180690
N2  - The clinical course of chronic lymphocytic leukemia (CLL) is highly variable. Patients with unmutated IGHV (U-CLL) usually progress rapidly, whereas patients with mutated IGHV (M-CLL) have a more indolent disease. The expression of several genes correlates closely with the IGHV mutational status and could be used to assess prognosis in CLL. We analyzed the prognostic relevance of COBLL1, LPL, and ZAP70 gene expression, which correlated with IGHV mutational status (p< 0.0001), in 117 CLL patients and established a prognostic parameter dividing the tested cohort according to the disease aggressiveness. Our prognostic parameter was validated on an independent cohort of 161 CLL patients and achieved a high accuracy (94%). Patients divided according to the prognostic parameter differ in overall survival and time to first treatment (p< 0.0001, HR = 2.300/5.970, 95% CI: 1.587-3.450/4.621-15.86). Our approach provides a reliable alternative method to prognosis assessment via IGHV mutational status analysis.
ER  -

PLEŠINGEROVÁ, Hana, Zuzana LIBROVA, Karla PLEVOVÁ, Antonín LIBRA, Boris TICHÝ, Hana SKUHROVÁ FRANCOVÁ, Filip VRBACKY, Lukáš SMOLEJ, Jiří MAYER, Vítězslav BRYJA, Michael DOUBEK and Šárka POSPÍŠILOVÁ. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. \textit{LEUKEMIA \&{} LYMPHOMA}. Oxon: TAYLOR \&{} FRANCIS LTD, 2017, vol.~58, No~1, p.~70-79. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2016.1180690.

Detailed Information on Publication Record